Case Number 6713
Request Date 16/05/2019
Completion Date 11/06/2019

 

Details of the Request

1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?

 

2. Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS;

  • RMS
  • PPMS
  • Not known

 

3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus).

Please provide the total number of patients by treatment for the following disease modifying drugs:

  • Aubagio (teriflunomide)
  • Avonex (interferon beta-1a)
  • Betaferon (interferon beta-1b)
  • Brabio (glatiramer acetate)
  • Copaxone (glatiramer acetate)
  • Extavia (beta interferon-1b)
  • Gilenya (fingolimod)
  • Lemtrada (alemtuzumab)
  • Mavenclad (cladribine)
  • Ocrevus (Ocrelizumab)
  • Plegridy (Peginterferon beta-1a)
  • Rebif (beta interferon-1a)
  • Tecfidera (dimethyl fumarate)
  • Tysabri (natalizumab)
  • Zinbryta (daclizumab)
  • Ampyra (Fampyra)

 

Details of the Response

1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?

324 patients were diagnosed with Multiple Sclerosis (MS) within the last 6 months (Nov 18 – Apr 19).

 

2. Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS;

The Trust does not hold this data. The Trust advises that there are no specific codes for relapsing (RMS) or primary progressive (PPMS).

 

3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:

Aubagio (teriflunomide) 11
Avonex (interferon beta-1a) 8
Betaferon (interferon beta-1b) 0
Brabio (glatiramer acetate) 17
Copaxone (glatiramer acetate) 36
Extavia (beta interferon-1b) 0
Gilenya (fingolimod) 38
Lemtrada (alemtuzumab) 4
Mavenclad (cladribine) 0
Ocrevus (Ocrelizumab) 0
Plegridy (Peginterferon beta-1a) 4
Rebif (beta interferon-1a) 12
Tecfidera (dimethyl fumarate) 62
Tysabri (natalizumab) 25
Zinbryta (daclizumab) 0
Ampyra (Fampyra) 0

Please note: some patients will have switched during the defined period, for example Copaxone to Brabio, or one drug to another and this may mean several patients are duplicated, however, as the question asks for ‘how many patients’ as an overall we have retained both entries for these patients.